We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


MDRNA, Inc. Announces Patent Allowance Covering Methods for Cell Specific Delivery of siRNAs

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MDRNA, Inc. Announces Patent Allowance Covering Methods for Cell Specific Delivery of siRNAs"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
MDRNA, Inc. has announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 12/701,397 covering methods for the delivery of siRNAs as well as a broad array of compounds with pharmacological activity.

The patent identifies and protects peptides that were discovered using MDRNA's proprietary Trp Cage Phage Display Library and describes targeting peptides that demonstrate high binding affinity to, and internalization by, hepatocellular carcinoma cells.

"Specificity to individual cell types and internalization are key attributes required for peptide-directed delivery," said Barry Polisky, Ph.D., Chief Scientific Officer of MDRNA. "The Trp Cage Phage Display Library is proving to be a robust means to screen and identify peptides that impart these targeting characteristics. The addition of these novel peptides to our proprietary DiLA2 delivery platform technology permits the potential development of highly tissue- and cell-specific RNAi-based therapies for the treatment of cancers in which the need to differentiate between normal and diseased cells is important."